Martin N Rossor

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1540316/publications.pdf

Version: 2024-02-01

518 papers	80,927 citations	1368 108 h-index	470 271 g-index
613 all docs	613 docs citations	613 times ranked	49198 citing authors

#	Article	IF	Citations
1	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 263-269.	0.4	12,681
2	Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 1991, 349, 704-706.	13.7	4,326
3	Current Concepts in Mild Cognitive Impairment. Archives of Neurology, 2001, 58, 1985.	4.9	4,117
4	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 2011, 134, 2456-2477.	3.7	3,913
5	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDSâ€“ADRDA criteria. Lancet Neurology, The, 2007, 6, 734-746.	4.9	3,755
6	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. New England Journal of Medicine, 2012, 367, 795-804.	13.9	3,005
7	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	9.4	2,697
8	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
9	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	9.4	1,708
10	Early-onset Alzheimer's disease caused by mutations at codon 717 of the Î²-amyloid precursor protein gene. Nature, 1991, 353, 844-846.	13.7	1,202
11	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	6.0	1,085
12	Potassium channel antibodyâ€associated encephalopathy: a potentially immunotherapyâ€responsive form of limbic encephalitis. Brain, 2004, 127, 701-712.	3.7	1,072
13	Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nature Genetics, 2005, 37, 806-808.	9.4	752
14	A Longitudinal Study of Brain Volume Changes in Normal Aging Using Serial Registered Magnetic Resonance Imaging. Archives of Neurology, 2003, 60, 989.	4.9	736
15	Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet, The, 1999, 353, 183-189.	6.3	675
16	11C-PiB PET assessment of change in fibrillar amyloid-Î² load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurology, The, 2010, 9, 363-372.	4.9	674
17	Neuropeptide Y distribution in human brain. Nature, 1983, 306, 584-586.	13.7	669
18	Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Annals of Neurology, 2001, 49, 433-442.	2.8	641

#	Article	IF	Citations
19	Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-registered serial MRI. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4703-4707.	3.3	613
20	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimerâ€™s disease. Nature Medicine, 2019, 25, 277-283.	15.2	610
21	The Effects of Donepezil in Alzheimerâ€™s Disease â€“ Results from a Multinational Trial¹. Dementia and Geriatric Cognitive Disorders, 1999, 10, 237-244.	0.7	540
22	Posterior cortical atrophy. Lancet Neurology, The, 2012, 11, 170-178.	4.9	487
23	The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nature Genetics, 1995, 11, 219-222.	9.4	461
24	Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type. Neuroscience Letters, 1980, 20, 373-377.	1.0	449
25	Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiology of Disease, 2008, 32, 412-419.	2.1	448
26	The diagnosis of young-onset dementia. Lancet Neurology, The, 2010, 9, 793-806.	4.9	435
27	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurology, The, 2015, 14, 253-262.	4.9	432
28	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.4	423
29	Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet, The, 2001, 358, 201-205.	6.3	414
30	Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. Nature, 1990, 347, 194-197.	13.7	407
31	Apolipoprotein E, É›4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Human Molecular Genetics, 1994, 3, 569-574.	1.4	400
32	Automatic Differentiation of Anatomical Patterns in the Human Brain: Validation with Studies of Degenerative Dementias. NeuroImage, 2002, 17, 29-46.	2.1	399
33	Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain, 2012, 135, 736-750.	3.7	392
34	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	4.9	383
35	Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet, The, 1996, 348, 94-97.	6.3	351
36	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950.	1.1	347

#	Article	IF	Citations
37	Using Serial Registered Brain Magnetic Resonance Imaging to Measure Disease Progression in Alzheimer Disease. Archives of Neurology, 2000, 57, 339.	4.9	346
38	Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimerâ€™s Disease. Science Translational Medicine, 2014, 6, 226ra30.	5.8	320
39	Regional variability of imaging biomarkers in autosomal dominant Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4502-9.	3.3	309
40	Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain, 2011, 134, 2565-2581.	3.7	306
41	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
42	Large C9orf72 Hexanucleotide Repeat Expansions Are Seen in Multiple Neurodegenerative Syndromes and Are More Frequent Than Expected in the UK Population. American Journal of Human Genetics, 2013, 92, 345-353.	2.6	297
43	Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurology, The, 2006, 5, 828-834.	4.9	292
44	Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease. Brain Research, 1980, 199, 147-160.	1.1	289
45	Research priorities to reduce the global burden of dementia by 2025. Lancet Neurology, The, 2016, 15, 1285-1294.	4.9	284
46	The clinical profile of right temporal lobe atrophy. Brain, 2009, 132, 1287-1298.	3.7	277
47	Loss of pigmented dopamine-Î²-hydroxylase positive cells from locus coeruleus in senile dementia of alzheimer's type. Neuroscience Letters, 1983, 39, 95-100.	1.0	270
48	C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurology, The, 2015, 14, 291-301.	4.9	270
49	A locus for familial earlyâ€“onset Alzhelmer's disease on the long arm of chromosome 14, proximal to the Î±1â€“antichymotrypsin gene. Nature Genetics, 1992, 2, 340-342.	9.4	266
50	A mutation in AlzheimerÊ¼s disease destroying a splice acceptor site in the presenilin-1 gene. NeuroReport, 1995, 7, 297-301.	0.6	262
51	Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neuroscience Letters, 1995, 186, 17-20.	1.0	245
52	Prion dementia without characteristic pathology. Lancet, The, 1990, 336, 7-9.	6.3	243
53	<scp>EFNSâ€ENS</scp> Guidelines on the diagnosis and management of disorders associated with dementia. European Journal of Neurology, 2012, 19, 1159-1179.	1.7	239
54	Frontotemporal dementia. BMJ, The, 2013, 347, f4827-f4827.	3.0	233

#	Article	IF	Citations
55	Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurology, The, 2009, 8, 334-344.	4.9	226
56	Progressive logopenic/phonological aphasia: Erosion of the language network. NeuroImage, 2010, 49, 984-993.	2.1	223
57	Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends in Neurosciences, 2013, 36, 561-569.	4.2	223
58	A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain, 2008, 131, 706-720.	3.7	222
59	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathologica, 2010, 120, 33-41.	3.9	222
60	Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. NeuroImage, 2010, 53, 1070-1076.	2.1	209
61	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2016, 3, 623-636.	1.7	207
62	Serum neurofilament light in familial Alzheimer disease. Neurology, 2017, 89, 2167-2175.	1.5	204
63	The substantia innominata in alzheimer's disease: an histochemical and biochemical study of cholinergic marker enzymes. Neuroscience Letters, 1982, 28, 217-222.	1.0	197
64	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology, 2018, 91, e1295-e1306.	1.5	193
65	Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet, The, 2003, 362, 1121-1122.	6.3	190
66	NON-CHOLINERGIC NEUROTRANSMITTER ABNORMALITIES IN ALZHEIMER'S DISEASE. British Medical Bulletin, 1986, 42, 70-74.	2.7	185
67	Primary progressive aphasia: a clinical approach. Journal of Neurology, 2018, 265, 1474-1490.	1.8	185
68	Developing an international network for Alzheimerâ€™s research: the Dominantly Inherited Alzheimer Network. Clinical Investigation, 2012, 2, 975-984.	0.0	180
69	Amyloid load and cerebral atrophy in Alzheimer's disease: An11C-PIB positron emission tomography study. Annals of Neurology, 2006, 60, 145-147.	2.8	178
70	Neurofilament inclusion body disease: a new proteinopathy?. Brain, 2003, 126, 2291-2303.	3.7	176
71	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
72	Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimerâ€™s disease. Brain, 2013, 136, 1399-1414.	3.7	174

#	Article	IF	Citations
73	Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer's disease. Neurobiology of Aging, 2011, 32, 1466-1476.	1.5	172
74	Familial non-specific dementia maps to chromosome 3. Human Molecular Genetics, 1995, 4, 1625-1628.	1.4	170
75	In vivo detection of microglial activation in frontotemporal dementia. Annals of Neurology, 2004, 56, 894-897.	2.8	170
76	Clinical phenotype and genetic associations in autosomal dominant familial Alzheimerâ€™s disease: a case series. Lancet Neurology, The, 2016, 15, 1326-1335.	4.9	163
77	Alzheimer's patients engage an alternative network during a memory task. Annals of Neurology, 2005, 58, 870-879.	2.8	158
78	Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neuroscience Letters, 1999, 259, 133-135.	1.0	156
79	Assessing the onset of structural change in familial Alzheimer's disease. Annals of Neurology, 2003, 53, 181-188.	2.8	152
80	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiology of Aging, 2018, 62, 191-196.	1.5	151
81	Complete analysis of the presenilin 1 gene in early onset AlzheimerÊ¼s disease. NeuroReport, 1996, 7, 801-805.	0.6	150
82	Alzheimer's pathology in primary progressive aphasia. Neurobiology of Aging, 2012, 33, 744-752.	1.5	148
83	Genetic Analysis of Inherited Leukodystrophies. JAMA Neurology, 2013, 70, 875.	4.5	147
84	The isolation of calculation skills. Journal of Neurology, 1995, 242, 78-81.	1.8	146
85	NEURONAL DEGENERATION IN LOCUS CERULEUS AND CORTICAL CORRELATES OF ALZHEIMER DISEASE. Alzheimer Disease and Associated Disorders, 1987, 1, 256-262.	0.6	145
86	Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. Lancet, The, 1999, 353, 2125.	6.3	145
87	Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathology and Applied Neurobiology, 2004, 30, 369-373.	1.8	145
88	Correlating familial Alzheimerâ€™s disease gene mutations with clinical phenotype. Biomarkers in Medicine, 2010, 4, 99-112.	0.6	145
89	Angiotensin Converting Enzyme in Alzheimer's Disease: Increased Activity in Caudate Nucleus and Cortical Areas. Journal of Neurochemistry, 1982, 38, 1490-1492.	2.1	143
90	Young onset dementia. Postgraduate Medical Journal, 2004, 80, 125-139.	0.9	139

#	Article	IF	Citations
91	Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease. NeuroImage, 2004, 23, 663-669.	2.1	139
92	Measurements of the Amygdala and Hippocampus in Pathologically Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Archives of Neurology, 2006, 63, 1434.	4.9	139
93	Reduced binding of [3H]ketanserin to cortical 5-HT2 receptors in senile dementia of the Alzheimer type. Neuroscience Letters, 1984, 44, 47-51.	1.0	138
94	A noveltau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Annals of Neurology, 2000, 48, 939-943.	2.8	136
95	Reduced corticol choline acetyltransferase activity in senile dementia of Alzheimer type is not accompanied by changes in vasoactive intestinal polypeptide. Brain Research, 1980, 201, 249-253.	1.1	135
96	Word-finding difficulty: a clinical analysis of the progressive aphasias. Brain, 2007, 131, 8-38.	3.7	135
97	Vasopressin, oxytocin and neurophysins in the human brain and spinal cord. Brain Research, 1984, 291, 111-117.	1.1	134
98	Magnetic Resonance Imaging Signatures of Tissue Pathology in Frontotemporal Dementia. Archives of Neurology, 2005, 62, 1402.	4.9	132
99	Pick's disease is associated with mutations in thetau gene. Annals of Neurology, 2000, 48, 859-867.	2.8	131
100	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	4.9	128
101	Brain biopsy in dementia. Brain, 2005, 128, 2016-2025.	3.7	127
102	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica, 2014, 127, 407-418.	3.9	123
103	VBM signatures of abnormal eating behaviours in frontotemporal lobar degeneration. NeuroImage, 2007, 35, 207-213.	2.1	122
104	Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial. Revue Neurologique, 2013, 169, 737-743.	0.6	122
105	Volumetric MRI and cognitive measures in Alzheimer disease. Journal of Neurology, 2008, 255, 567-574.	1.8	121
106	Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Neuroscience, 1988, 25, 419-438.	1.1	117
107	Patterns of longitudinal brain atrophy in the logopenic variant of primary progressive aphasia. Brain and Language, 2013, 127, 121-126.	0.8	116
108	Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Human Molecular Genetics, 2015, 24, 5260-5269.	1.4	116

#	Article	IF	Citations
109	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimerâ€™s disease. Brain, 2018, 141, 3065-3080.	3.7	116
110	Intracranial Volume and Alzheimer Disease. Archives of Neurology, 2000, 57, 220.	4.9	115
111	The Genetic and Pathological Classification of Familial Frontotemporal Dementia. Archives of Neurology, 2001, 58, 1813.	4.9	114
112	Regional Distribution of Neurotensin in Human Brain. Journal of Neurochemistry, 1982, 38, 1777-1780.	2.1	113
113	Syndromes of nonfluent primary progressive aphasia. Neurology, 2010, 75, 603-610.	1.5	113
114	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1111.	4.5	112
115	Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. Journal of the Neurological Sciences, 1980, 48, 303-313.	0.3	109
116	Huntington's disease phenocopies are clinically and genetically heterogeneous. Movement Disorders, 2008, 23, 716-720.	2.2	108
117	Distribution of Cholecystokinin-Like Peptides in the Human Brain. Journal of Neurochemistry, 1982, 38, 1177-1179.	2.1	102
118	Profiles of white matter tract pathology in frontotemporal dementia. Human Brain Mapping, 2014, 35, 4163-4179.	1.9	102
119	Differentiating AD from aging using semiautomated measurement of hippocampal atrophy rates. NeuroImage, 2004, 23, 574-581.	2.1	101
120	Visual Assessment of Atrophy on Magnetic Resonance Imaging in the Diagnosis of Pathologically Confirmed Young-Onset Dementias. Archives of Neurology, 2005, 62, 1410.	4.9	101
121	Topographical shortâ€term memory differentiates Alzheimer's disease from frontotemporal lobar degeneration. Hippocampus, 2010, 20, 1154-1169.	0.9	101
122	Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. Neuroscience Letters, 2003, 336, 167-170.	1.0	99
123	Assessing quality of life in dementia: Preliminary psychometric testing of the Quality of Life Assessment Schedule (QOLAS). Neuropsychological Rehabilitation, 2001, 11, 219-243.	1.0	98
124	A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia. Neurodegenerative Diseases, 2007, 4, 185-194.	0.8	97
125	White matter tract signatures of the progressive aphasias. Neurobiology of Aging, 2013, 34, 1687-1699.	1.5	97
126	R47H TREM2 variant increases risk of typical earlyâ€onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimer's and Dementia, 2014, 10, 602.	0.4	94

#	Article	IF	Citations
127	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.4	93
128	A new variant of prion disease. Lancet, The, 1996, 347, 916-917.	6.3	91
129	Pain and temperature processing in dementia: a clinical and neuroanatomical analysis. Brain, 2015, 138, 3360-3372.	3.7	90
130	Familial Alzheimer's disease with the amyloid precursor protein position 717 mutation and sporadic Alzheimer's disease have the same cytoskeletal pathology. Neuroscience Letters, 1992, 137, 221-224.	1.0	87
131	Reduced Cortical Thickness in the Posterior Cingulate Gyrus is Characteristic of Both Typical and Atypical Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 587-598.	1.2	87
132	Neurological manifestations of autosomal dominant familial Alzheimerâ€™s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurology, The, 2016, 15, 1317-1325.	4.9	87
133	Apraxia in progressive nonfluent aphasia. Journal of Neurology, 2010, 257, 569-574.	1.8	86
134	Reduction in cholecystokinin-like immunoreactivity in the basal ganglia in Huntington's disease. Brain Research, 1980, 198, 497-500.	1.1	84
135	Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. International Journal of Geriatric Psychiatry, 2003, 18, 67-72.	1.3	84
136	Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurology, The, 2018, 17, 123-132.	4.9	84
137	Functional cognitive disorder: dementiaâ€™s blind spot. Brain, 2020, 143, 2895-2903.	3.7	84
138	Does Alzheimerâ€™s Disease Affect Hippocampal Asymmetry? Evidence from a Cross-Sectional and Longitudinal Volumetric MRI Study. Dementia and Geriatric Cognitive Disorders, 2005, 19, 338-344.	0.7	83
139	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimerâ€™s disease. Brain, 2018, 141, 1186-1200.	3.7	83
140	Patients with a novel neurofilamentopathy: dementia with neurofilament inclusions. Neuroscience Letters, 2003, 341, 177-180.	1.0	81
141	Monitoring cognitive changes: Psychometric properties of six cognitive tests. British Journal of Clinical Psychology, 2004, 43, 197-210.	1.7	79
142	Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain, 2011, 134, 293-300.	3.7	79
143	Cerebrospinal fluid in the differential diagnosis of Alzheimerâ€™s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimer's Research and Therapy, 2018, 10, 32.	3.0	79
144	Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in senile dementia of Alzheimer type. Neuroscience Letters, 1986, 70, 154-159.	1.0	78

#	Article	IF	Citations
145	A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain, 2011, 134, 2548-2564.	3.7	76
146	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimerâ€™s disease: a longitudinal cohort study. Molecular Psychiatry, 2021, 26, 5967-5976.	4.1	76
147	Prospective Study of HTLV-I Infection in an Initially Asymptomatic Cohort. Journal of Acquired Immune Deficiency Syndromes, 1999, 22, 92.	0.3	74
148	Some workmen can blame their tools: artistic change in an individual with Alzheimer's disease. Lancet, The, 2001, 357, 2129-2133.	6.3	74
149	Receptive prosody in nonfluent primary progressive aphasias. Cortex, 2012, 48, 308-316.	1.1	74
150	Normal cortical concentration of cholecystokinin-like immunoreactivity with reduced choline acetyltransferase activity in senile dementia of Alzheimer type. Life Sciences, 1981, 29, 405-410.	2.0	73
151	Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD. Neurobiology of Aging, 2007, 28, 20-28.	1.5	72
152	DEMENTIA AND PARKINSON'S DISEASE â€" PATHHOLOGICAL AND NEUROCHEMICAL CONSIDERATIONS. British Medical Bulletin, 1986, 42, 86-90.	2.7	71
153	Screening for mutations in the open reading frame and promoter of the Î²-amyloid precursor protein gene in familial Alzheimer's disease: identification of a further family with APP717 Valâ†'Ile. Human Molecular Genetics, 1992, 1, 165-168.	1.4	71
154	Longitudinal Patterns of Regional Change on Volumetric MRI in Frontotemporal Lobar Degeneration. Dementia and Geriatric Cognitive Disorders, 2004, 17, 307-310.	0.7	70
155	BDNFVal66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimerâ€™s disease. Brain, 2016, 139, 2766-2777.	3.7	70
156	Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer's Disease but is not causative. American Journal of Medical Genetics Part A, 1995, 60, 1-6.	2.4	69
157	Consent recommendations for research and international data sharing involving persons with dementia. Alzheimer's and Dementia, 2018, 14, 1334-1343.	0.4	68
158	Extrahypothalamic vasopressin in human brain. Brain Research, 1981, 214, 349-355.	1.1	67
159	Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. Neurobiology of Aging, 2012, 33, 426.e13-426.e21.	1.5	67
160	The pattern of atrophy in familial Alzheimer disease. Neurology, 2013, 81, 1425-1433.	1.5	67
161	Early behavioural changes in familial Alzheimerâ€™s disease in the Dominantly Inherited Alzheimer Network. Brain, 2015, 138, 1036-1045.	3.7	67
162	Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls. Neurobiology of Aging, 2013, 34, 1996-2002.	1.5	66

#	Article	IF	Citations
163	Segregation of functional networks is associated with cognitive resilience in Alzheimerâ€™s disease. Brain, 2021, 144, 2176-2185.	3.7	66
164	Clinical and Positron Emission Tomographic Studies in the 'Extrapyramidal Syndrome' of Dementia of the Alzheimer Type. Archives of Neurology, 1990, 47, 1318-1323.	4.9	65
165	Increased S100Î² in the cerebrospinal fluid of patients with frontotemporal dementia. Neuroscience Letters, 1997, 235, 5-8.	1.0	65
166	Apolipoprotein E Genotype Modifies the Phenotype of Alzheimer Disease. Archives of Neurology, 2006, 63, 155.	4.9	65
167	Human herpesvirus infections and dementia or mild cognitive impairment: a systematic review and meta-analysis. Scientific Reports, 2019, 9, 4743.	1.6	65
168	<scp>CSF</scp> progranulin increases in the course of Alzheimer's disease and is associated with <scp>sTREM</scp> 2, neurodegeneration and cognitive decline. EMBO Molecular Medicine, 2018, 10, .	3.3	64
169	Longitudinal neuroanatomical and cognitive progression of posterior cortical atrophy. Brain, 2019, 142, 2082-2095.	3.7	64
170	Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7619-7623.	3.3	63
171	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. NeuroImage: Clinical, 2017, 15, 171-180.	1.4	63
172	Diagnosis and management of Alzheimerâ€™s disease and other disorders associated with dementia. The role of neurologists in Europe. European Journal of Neurology, 2000, 7, 133.	1.7	63
173	Familial dementia with swollen achromatic neurons and corticobasal inclusion bodies: a clinical and pathological study. Journal of the Neurological Sciences, 1996, 135, 21-30.	0.3	62
174	Purkinje cell loss and astrocytosis in the cerebellum in familial and sporadic Alzheimer's disease. Neuroscience Letters, 1996, 214, 33-36.	1.0	62
175	Structural neuroanatomy of tinnitus and hyperacusis in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1274-1278.	0.9	62
176	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 614-628.	4.1	61
177	Application of Automated Medial Temporal Lobe Atrophy Scale to Alzheimer Disease. Archives of Neurology, 2007, 64, 849.	4.9	60
178	Detailed volumetric analysis of the hypothalamus in behavioral variant frontotemporal dementia. Journal of Neurology, 2015, 262, 2635-2642.	1.8	60
179	Validation of next-generation sequencing technologies in genetic diagnosis of dementia. Neurobiology of Aging, 2014, 35, 261-265.	1.5	59
180	Lewy bodies in the brain of two members of a family with the 717 (Val to Ile) mutation of the amyloid precursor protein gene. Neuroscience Letters, 1994, 172, 77-79.	1.0	58

#	Article	IF	Citations
181	Transportin1: a marker of FTLD-FUS. Acta Neuropathologica, 2011, 122, 591-600.	3.9	58
182	Presymptomatic cortical thinning in familial Alzheimer disease. Neurology, 2016, 87, 2050-2057.	1.5	58
183	Hereditary leukoencephalopathy with axonal spheroids: a spectrum of phenotypes from CNS vasculitis to parkinsonism in an adult onset leukodystrophy series. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 512-519.	0.9	58
184	Atrophy of the Hippocampal Formation in Early Familial Alzheimer's Disease. Annals of the New York Academy of Sciences, 1996, 777, 226-232.	1.8	57
185	ApoE genotype is a risk factor in nonpresenilin early-onset alzheimer's disease families. , 1998, 81, 117-121.		57
186	Dopamine-D-1 and D-2 receptors in Huntington's disease. European Journal of Pharmacology, 1983, 88, 223-229.	1.7	56
187	The Natural History of Alzheimer Disease. Archives of Neurology, 2004, 61, 1743.	4.9	56
188	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain, 2017, 140, 1784-1791.	3.7	55
189	The Role of Variation at AÎ²PP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 377-387.	1.2	53
190	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. Neurobiology of Aging, 2015, 36, 3140-3151.	1.5	53
191	Parietal Lobe Deficits in Frontotemporal Lobar Degeneration Caused by a Mutation in the Progranulin Gene. Archives of Neurology, 2008, 65, 506.	4.9	52
192	The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2017, 9, 85.	3.0	52
193	Dementia wellbeing and COVIDâ€19: Review and expert consensus on current research and knowledge gaps. International Journal of Geriatric Psychiatry, 2021, 36, 1597-1639.	1.3	52
194	Genetic Variability in CLU and Its Association with Alzheimer's Disease. PLoS ONE, 2010, 5, e9510.	1.1	52
195	Morphological overlap between corticobasal degeneration and Pick's disease: A clinicopathological report. Movement Disorders, 1995, 10, 111-114.	2.2	51
196	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1427-1437.	0.4	51
197	Alzheimerâ€™s disease in the 100 years since Alzheimerâ€™s death. Brain, 2015, 138, 3816-3821.	3.7	50
198	Association between autoimmune thyroid disease and Familial Alzheimers disease. Clinical Endocrinology, 1991, 35, 93-96.	1.2	49

#	Article	IF	Citations
199	Quantitative Magnetization Transfer Imaging in Alzheimer Disease. Radiology, 2007, 244, 832-837.	3.6	49
200	Extensive and Temporally Ungraded Retrograde Amnesia in Encephalitis Associated With Antibodies to Voltage-Gated Potassium Channels. Archives of Neurology, 2007, 64, 404.	4.9	49
201	Neuropsychological correlates of whole brain atrophy in Alzheimer's disease. Neuropsychologia, 2008, 46, 1732-1737.	0.7	49
202	Autonomic failure preceding dementia with Lewy bodies. Journal of Neurology, 2000, 247, 229-231.	1.8	48
203	An automated algorithm for the computation of brain volume change from sequential MRIs using an iterative principal component analysis and its evaluation for the assessment of whole-brain atrophy rates in patients with probable Alzheimer's disease. NeuroImage, 2004, 22, 134-143.	2.1	48
204	Auditory hedonic phenotypes in dementia: AÂbehavioural and neuroanatomical analysis. Cortex, 2015, 67, 95-105.	1.1	48
205	Age of onset in familial early onset Alzheimer's disease correlates with genetic aetiology. American Journal of Medical Genetics Part A, 1993, 48, 129-130.	2.4	47
206	Novel L284R <i>MAPT </i>Mutation in a Family with an Autosomal Dominant Progressive Supranuclear Palsy Syndrome. Neurodegenerative Diseases, 2011, 8, 149-152.	0.8	47
207	Rates of Hemispheric and Lobar Atrophy in the Language Variants of Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2012, 30, 407-411.	1.2	47
208	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's diseaseâ€informed machineâ€learning. Alzheimer's and Dementia, 2020, 16, 501-511.	0.4	47
209	Delusions in frontotemporal lobar degeneration. Journal of Neurology, 2009, 256, 600-7.	1.8	46
210	Concentration of Serum Amyloid P Component in the CSF as a Possible Marker of Cerebral Amyloid Deposits in Alzheimerâ€²s Disease. Biochemical and Biophysical Research Communications, 1994, 201, 722-726.	1.0	45
211	Mapping the progression of progranulin-associated frontotemporal lobar degeneration. Nature Clinical Practice Neurology, 2008, 4, 455-460.	2.7	45
212	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1197-1206.	0.4	45
213	The Dementias Platform UK (DPUK) Data Portal. European Journal of Epidemiology, 2020, 35, 601-611.	2.5	45
214	Molecular Genetic Characterisation of Frontotemporal Dementia on Chromosome 3. Dementia and Geriatric Cognitive Disorders, 1999, 10, 93-101.	0.7	44
215	Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research. PLoS ONE, 2012, 7, e43099.	1.1	44
216	Presymptomatic studies in genetic frontotemporal dementia. Revue Neurologique, 2013, 169, 820-824.	0.6	44

#	Article	IF	Citations
217	A Volumetric Magnetic Resonance Imaging Study of the Amygdala in Frontotemporal Lobar Degeneration and Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2005, 20, 238-244.	0.7	43
218	Combining short interval MRI in Alzheimerâ€™s disease. Journal of Neurology, 2006, 253, 1147-1153.	1.8	43
219	Acceleration of cortical thinning in familial Alzheimer's disease. Neurobiology of Aging, 2011, 32, 1765-1773.	1.5	43
220	Neuroanatomical profiles of personality change in frontotemporal lobar degeneration. British Journal of Psychiatry, 2011, 198, 365-372.	1.7	43
221	Alzheimer's Disease Families with Amyloid Precursor Protein Mutationsa. Annals of the New York Academy of Sciences, 1993, 695, 198-202.	1.8	42
222	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 1225.	1.6	42
223	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: AÂserial magnetic resonance imaging study. Alzheimer's and Dementia, 2018, 14, 43-53.	0.4	42
224	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	2.8	42
225	Comparison of arterial spin labeling registration strategies in the multiâ€center GENetic frontotemporal dementia initiative (GENFI). Journal of Magnetic Resonance Imaging, 2018, 47, 131-140.	1.9	41
226	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. Brain, 2019, 142, 1108-1120.	3.7	41
227	Insertions in the prion protein gene in atypical dementias. Experimental Neurology, 1991, 112, 240-242.	2.0	40
228	Amnesia, cerebral atrophy, and autoimmunity. Lancet, The, 2003, 361, 1266.	6.3	40
229	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 2018, 62, 245.e9-245.e12.	1.5	40
230	Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia. Neurocase, 2018, 24, 166-174.	0.2	40
231	A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Annals of Neurology, 2000, 48, 939-43.	2.8	40
232	Sequencing of exons 16 and 17 of the Î²-amyloid precursor protein gene in 14 families with early onset Alzheimer's disease fails to reveal mutations in the Î²-amyloid sequence. Neuroscience Letters, 1991, 133, 1-2.	1.0	39
233	Prion protein immunocytochemistry helps to establish the true incidence of prion diseases. Neuroscience Letters, 1992, 147, 67-71.	1.0	39
234	Confirmation that familial clustering and age of onset in late onset Alzheimer's disease are determined at the apolipoprotein E locus. Neuroscience Letters, 1994, 174, 222-224.	1.0	39

#	Article	IF	Citations
235	Dissecting IWG-2 typical and atypical Alzheimerâ€™s disease: insights from cerebrospinal fluid analysis. Journal of Neurology, 2015, 262, 2722-2730.	1.8	39
236	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39
237	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the <scp>GENFI</scp> cohort: A crossâ€sectional diffusion tensor imaging study. Annals of Clinical and Translational Neurology, 2018, 5, 1025-1036.	1.7	39
238	Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. Brain Stimulation, 2020, 13, 1031-1039.	0.7	39
239	Plasma levodopa, dopamine and therapeutic response following levodopa therapy of Parkinsonian patients. Journal of the Neurological Sciences, 1980, 46, 385-392.	0.3	38
240	Sporadic fatal insomnia: A case study. Annals of Neurology, 2000, 48, 665-669.	2.8	38
241	Cases of Alzheimer's disease due to deletion of exon 9 of the presenilin-1 gene show an unusual but characteristic Î²-amyloid pathology known as â€˜cotton woolâ€™ plaques. Neuropathology and Applied Neurobiology, 2001, 27, 189-196.	1.8	37
242	A pathogenic progranulin mutation and <scp>C9orf72</scp> repeat expansion in a family with frontotemporal dementia. Neuropathology and Applied Neurobiology, 2014, 40, 502-513.	1.8	37
243	Alteractions in brain opiate receptors in Parkinson's disease. Brain Research, 1979, 173, 378-382.	1.1	36
244	No Evidence for Lateral Asymmetry of Neurotransmitters in Post-Mortem Human Brain. Journal of Neurochemistry, 1980, 35, 743-745.	2.1	36
245	Neurotensin in human brain: Regional distribution and effects of neurological illness. Brain Research, 1985, 347, 239-244.	1.1	36
246	Genetic Influences on Atrophy Patterns in Familial Alzheimer's Disease: A Comparison of APP and PSEN1 Mutations. Journal of Alzheimer's Disease, 2013, 35, 199-212.	1.2	36
247	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimerâ€™s disease. Brain, 2019, 142, 1429-1440.	3.7	36
248	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.4	36
249	Mental symptoms in Huntington's disease and a possible primary aminergic neuron lesion. Science, 1980, 210, 1369-1371.	6.0	35
250	A novel technique for the quantitative assessment of apraxic deficits: Application to individuals with mild cognitive impairment. Journal of Neuropsychology, 2007, 1, 237-257.	0.6	35
251	Amaurosis fugax in young people.. British Journal of Ophthalmology, 1992, 76, 660-662.	2.1	34
252	Selective Sparing of Verb Naming in a Case of Severe Alzheimer's Disease. Cortex, 1999, 35, 443-450.	1.1	34

#	Article	IF	Citations
253	Dementia and driving: European National Guidelines. European Journal of Neurology, 2000, 7, 745-745.	1.7	34
254	The Quantitative Assessment of Apraxic Deficits in Alzheimer's Disease. Cortex, 2007, 43, 976-986.	1.1	34
255	Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series. Molecular Psychiatry, 2020, 25, 3399-3412.	4.1	34
256	The regional distribution and chromatographic behaviour of somatostatin in human brain. Neuroscience Letters, 1981, 22, 319-324.	1.0	33
257	Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Valâ†'Ile) mutation cases: A morphometric investigation. Journal of the Neurological Sciences, 1997, 149, 177-184.	0.3	33
258	CANDID?counselling and diagnosis in dementia: a national telemedicine service supporting the care of younger patients with dementia. , 1998, 13, 381-388.		33
259	Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration. Neurobiology of Aging, 2009, 30, 656-665.	1.5	33
260	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	2.1	33
261	â€œâ€"but who is that on the other side of you?â€•Extracampine hallucinations revisited. Lancet, The, 2002, 360, 2064-2066.	6.3	32
262	The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1405-1407.	0.9	32
263	Ornithine aminotransferase in Huntington's disease. Brain Research, 1982, 231, 466-471.	1.1	31
264	Test-retest reliability, practice effects and reliable change indices for the recognition memory test. British Journal of Clinical Psychology, 2003, 42, 407-425.	1.7	31
265	Altered body schema processing in frontotemporal dementia with C9ORF72 mutations. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1016-1023.	0.9	31
266	Benzodiazepine receptors: The effect of GABA on their characteristics in human brain and their alteration in Huntington's disease. Brain Research, 1980, 199, 79-88.	1.1	30
267	Î²A4 protein deposition in familial Alzheimer's disease with the mutation in codon 717 of the Î²A4 amyloid precursor protein gene and sporadic Alzheimer's disease. Neuroscience Letters, 1993, 149, 137-140.	1.0	30
268	The prevalence of oligoclonal bands in the CSF of patients with primary neurodegenerative dementia. Journal of Neurology, 2004, 251, 184-188.	1.8	30
269	A novel exon 2 I27V VCP variant is associated with dissimilar clinical syndromes. Journal of Neurology, 2011, 258, 1494-1496.	1.8	30
270	Extrahypothalamic vasopressin is unchanged in Parkinson's disease and Huntington's disease. Brain Research, 1982, 253, 341-343.	1.1	29

#	Article	IF	Citations
271	Regional Distribution of Pro-Opiomelanocortin-Derived Peptides in the Human Brain. Neuroendocrinology, 1984, 38, 45-50.	1.2	29
272	Molecular pathology of Alzheimer's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 583-586.	0.9	29
273	Clinical and Neuroimaging Features of Familial Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1996, 777, 49-56.	1.8	29
274	Evidence for Allelic Heterogeneity in Familial Early-Onset Alzheimer's Disease. British Journal of Psychiatry, 1991, 158, 471-474.	1.7	28
275	Cognitive profile in dementia associated with vitamin B 12 deficiency due to pernicious anaemia. Journal of Neurology, 1999, 246, 317-319.	1.8	28
276	Hereditary Vascular Dementia Linked to Notch 3 Mutations: CADASIL in British Families. Annals of the New York Academy of Sciences, 2000, 903, 293-298.	1.8	28
277	the mini mental state examination. Practical Neurology, 2005, 5, 298-303.	0.5	28
278	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	1.4	28
279	Positron Emission Tomography in Familial Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1995, 9, 17-20.	0.6	27
280	Apolipoprotein E genotype does not affect the age of onset of dementia in families with defined tau mutations. Neuroscience Letters, 1999, 260, 193-195.	1.0	27
281	Neologistic jargon aphasia and agraphia in primary progressive aphasia. Journal of the Neurological Sciences, 2009, 277, 155-159.	0.3	27
282	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology, 2015, 85, 790-798.	1.5	27
283	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	1.4	27
284	Seizures as an early symptom of autosomal dominant Alzheimer's disease. Neurobiology of Aging, 2019, 76, 18-23.	1.5	27
285	Clinical Features of Sporadic and Familial Alzheimer's Disease. Experimental Neurology, 1996, 5, 393-397.	1.7	26
286	Autopsy-Confirmed Familial Early-Onset Alzheimer Disease Caused by the L153V Presenilin 1 Mutation. Archives of Neurology, 2001, 58, 953.	4.9	26
287	Sporadic and Familial Dementia With Ubiquitin-Positive Tau-Negative Inclusions. Archives of Neurology, 2005, 62, 1097.	4.9	26
288	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	1.1	26

#	Article	IF	Citations
289	Acquired Brown's syndrome: an unusual cause.. British Journal of Ophthalmology, 1985, 69, 791-794.	2.1	25
290	Regional brain metabolite abnormalities in inherited prion disease and asymptomatic gene carriers demonstrated in vivo by quantitative proton magnetic resonance spectroscopy. Neuroradiology, 2006, 48, 428-433.	1.1	25
291	The distribution and characterisation of thyrotrophin releasing hormone (TRH) in the human brain. Neuropeptides, 1981, 2, 115-122.	0.9	24
292	Sciatic nerve damage due to toilet seat entrapment: another Saturday night palsy.. Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 1113-1115.	0.9	24
293	Evidence of a founder effect in families with frontotemporal dementia that harbor the tau +16 splice mutation. American Journal of Medical Genetics Part A, 2004, 125B, 79-82.	2.4	24
294	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
295	Evidence for Multiple Muscarinic Receptor Subtypes in Human Brain. Journal of Neurochemistry, 1984, 43, 299-302.	2.1	23
296	BRAIN MUSCARINIC RECEPTORS IN ALZHEIMER'S AND PARKINSON'S DISEASES. Lancet, The, 1989, 334, 1279.	6.3	23
297	Apolipoprotein E genotyping in Alzheimer's disease. Lancet, The, 1996, 347, 1775-1776.	6.3	23
298	Provisional clinical and neuroradiological criteria for the diagnosis of Pick's disease. European Journal of Neurology, 1998, 5, 519-520.	1.7	23
299	EFNS task force on molecular diagnosis of neurologic disorders Guidelines for the molecular diagnosis of inherited neurologic diseases First of two parts. European Journal of Neurology, 2001, 8, 299-314.	1.7	23
300	Differing patterns of temporal atrophy in Alzheimerâ€™s disease and semantic dementia. Neurology, 2002, 58, 838-838.	1.5	23
301	Increased hippocampal atrophy rates in AD over 6 months using serial MR imaging. Neurobiology of Aging, 2008, 29, 1199-1203.	1.5	23
302	Toward common mechanisms for risk factors in Alzheimer's syndrome. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 571-578.	1.8	23
303	Pathogenic presenilin 1 mutations (P436S & I143F) in early-onset Alzheimer's disease in the UK. , 1999, 13, 256-256.		22
304	Artistic Changes in Alzheimer's Disease. International Review of Neurobiology, 2006, 74, 147-161.	0.9	22
305	A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study. Alzheimer's Research and Therapy, 2018, 10, 44.	3.0	22
306	Scintigraphy with 123I-Serum Amyloid P Component in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1998, 12, 208-210.	0.6	21

#	Article	IF	Citations
307	Dementia With Lewy Bodies Studied With Positron Emission Tomography. Archives of Neurology, 2001, 58, 505-8.	4.9	21
308	Voxel-Based Morphometry in Tau-Positive and Tau-Negative Frontotemporal Lobar Degenerations. Neurodegenerative Diseases, 2004, 1, 225-230.	0.8	21
309	Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?. Journal of Alzheimer's Disease, 2016, 54, 1297-1302.	1.2	21
310	Neuropeptides in degenerative disease of the central nervous system. Trends in Neurosciences, 1982, 5, 399-401.	4.2	20
311	PRESENILE DEMENTIA ASSOCIATED WITH MOSAIC TRISOMY 21 IN A PATIENT WITH A DOWN SYNDROME CHILD. Lancet, The, 1989, 334, 743.	6.3	20
312	Differential Diagnosis of Frontotemporal Dementia: Pickâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 1999, 10, 43-45.	0.7	20
313	Neuropsychological profiles of familial Alzheimer's disease associated with mutations in the presenilin 1 and amyloid precursor protein genes. Journal of Neurology, 2001, 248, 45-50.	1.8	20
314	Short TE Quantitative Proton Magnetic Resonance Spectroscopy in Variant Creutzfeldt-Jakob Disease. European Radiology, 2006, 16, 1692-1698.	2.3	20
315	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	1.5	20
316	Central alveolar hypoventilation associated with paraneoplastic brain-stem encephalitis and anti-Hu antibodies. Journal of Neurology, 1994, 241, 561-566.	1.8	19
317	Distinguishable effects of Presenilin-1 and APP717 mutations on amyloid plaque deposition. Neurobiology of Aging, 2001, 22, 367-376.	1.5	19
318	Delineating the sites and progression of in vivo atrophy in multiple system atrophy using fluid-registered MRI. Movement Disorders, 2003, 18, 955-958.	2.2	19
319	Abnormal laughter-like vocalisations replacing speech in primary progressive aphasia. Journal of the Neurological Sciences, 2009, 284, 120-123.	0.3	19
320	Can we model a cognitive footprint of interventions and policies to help to meet the global challenge of dementia?. Lancet, The, 2015, 386, 1008-1010.	6.3	19
321	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	2.8	19
322	Thalamic degeneration with negative prion protein immunostaining. Journal of Neurology, 2000, 247, 48-51.	1.8	18
323	The Alien Limb. Practical Neurology, 2004, 4, 44-45.	0.5	18
324	Automated Measurement of Hippocampal Atrophy Using Fluid-Registered Serial MRI in AD and Controls. Journal of Computer Assisted Tomography, 2007, 31, 581-587.	0.5	18

#	Article	IF	Citations
325	A novel A781V mutation in the CSF1R gene causes hereditary diffuse leucoencephalopathy with axonal spheroids. Journal of the Neurological Sciences, 2013, 332, 141-144.	0.3	18
326	Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 112.	3.0	18
327	Dementia and driving: Results of a semi-realistic simulator study. International Journal of Geriatric Psychiatry, 1995, 10, 859-864.	1.3	17
328	A Comparison of Î²-Amyloid Deposition in the Medial Temporal Lobe in Sporadic Alzheimer's Disease, Down's Syndrome and Normal Elderly Brains. Experimental Neurology, 1996, 5, 35-41.	1.7	17
329	Presymptomatic Generalized Brain Atrophy in Frontotemporal Dementia Caused by CHMP2B Mutation. Dementia and Geriatric Cognitive Disorders, 2009, 27, 182-186.	0.7	17
330	No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 764-771.	1.1	17
331	Binary reversals in primary progressive aphasia. Cortex, 2016, 82, 287-289.	1.1	17
332	Donepezil enhances understanding of degraded speech in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2017, 4, 835-840.	1.7	17
333	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 440-446.	1.2	16
334	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. NeuroImage, 2019, 188, 282-290.	2.1	16
335	A correlative study on hippocampal cation shifts and amino acids and clinico-pathological data in Alzheimer's disease. Neurobiology of Aging, 1987, 8, 487-494.	1.5	15
336	National survey to assess current practices in the diagnosis and management of young people with dementia. International Journal of Geriatric Psychiatry, 2002, 17, 124-127.	1.3	15
337	The Uncertain Nosology of Hashimoto Encephalopathy. Archives of Neurology, 2003, 60, 1812.	4.9	15
338	Shunt responsive progressive supranuclear palsy?. Movement Disorders, 2007, 22, 902-903.	2.2	15
339	Memory complaints and increased rates of brain atrophy: risk factors for mild cognitive impairment and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2010, 25, 1119-1126.	1.3	15
340	Cerebral microbleeds in familial Alzheimer's disease. Brain, 2012, 135, e201-e201.	3.7	15
341	Management of neurological disorders: dementia.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1451-1456.	0.9	14
342	Dementia associated with haemochromatosis: a report of two cases. European Journal of Neurology, 1997, 4, 318-322.	1.7	14

#	Article	IF	Citations
343	A Case of Sporadic Pick Disease With Onset at 27 Years. Archives of Neurology, 1999, 56, 1289.	4.9	14
344	Unravelling the disease process. Lancet, The, 2001, 358, S1.	6.3	14
345	Prion protein (PRNP) genotypes in frontotemporal lobar degeneration syndromes. Annals of Neurology, 2006, 60, 616-616.	2.8	14
346	TDP43 pathology in the brain, spinal cord, and dorsal root ganglia of a patient with FOSMN. Neurology, 2019, 92, e951-e956.	1.5	14
347	Post-Mortem Neurochemical Changes in Alzheimer's Disease Compared With Normal Ageing. Canadian Journal of Neurological Sciences, 1986, 13, 499-502.	0.3	13
348	Education and training of European neurologists in dementia. European Journal of Neurology, 2007, 14, 505-509.	1.7	13
349	Olfactory impairment in posterior cortical atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 588-590.	0.9	13
350	Suspecting dementia: canaries, chameleons and zebras. Practical Neurology, 2021, 21, 300-312.	0.5	13
351	Early Implementation and Evaluation of StepUp for Dementia Research: An Australia-Wide Dementia Research Participation and Public Engagement Platform. International Journal of Environmental Research and Public Health, 2021, 18, 11353.	1.2	13
352	Biological markers in mental disorders: Post-mortem studies. Journal of Psychiatric Research, 1984, 18, 457-465.	1.5	12
353	Apolipoprotein E alleles but neither apolipoprotein B nor apolipoprotein AI/CIII alleles are associated with late onset, familial Alzheimer's disease. Neuroscience Letters, 1995, 188, 202-204.	1.0	12
354	Symptoms of Memory Loss as Predictors of Cognitive Impairment?. Alzheimer Disease and Associated Disorders, 2007, 21, 101-106.	0.6	12
355	A cognitive chameleon: Lessons from a novelMAPTmutation case. Neurocase, 2014, 20, 684-694.	0.2	12
356	Effect of donepezil on transcranial magnetic stimulation parameters in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 103-107.	1.8	12
357	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	3.0	12
358	Snouting, Pouting and Rooting. Practical Neurology, 2001, 1, 119-121.	0.5	11
359	A novel presenilin 1 deletion (p.L166del) associated with early onset familial Alzheimer's disease. European Journal of Neurology, 2007, 14, 829-831.	1.7	11
360	HECTD2, a candidate susceptibility gene for Alzheimer's disease on 10q. BMC Medical Genetics, 2009, 10, 90.	2.1	11

#	Article	IF	Citations
361	Defining and describing the pre-dementia stages of familial Alzheimer's disease. Alzheimer's Research and Therapy, 2011, 3, 29.	3.0	11
362	Impaired self-other differentiation in frontotemporal dementia due to the C9ORF72 expansion. Alzheimer's Research and Therapy, 2012, 4, 42.	3.0	11
363	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	1.2	11
364	Incidence, morbidity, mortality and disparities in dementia: A population linked electronic health records study of 4.3 million individuals. Alzheimer's and Dementia, 2023, 19, 123-135.	0.4	11
365	Genetic characterization of a familial non-specific dementia originating in Jutland, Denmark. Journal of the Neurological Sciences, 1993, 114, 138-143.	0.3	10
366	Protein Folding, Nucleation Phenomena and Delayed Neurodegeneration in Alzheimer's Disease. Reviews in the Neurosciences, 1996, 7, 21-8.	1.4	10
367	Alzheimerâ€™s disease: towards therapeutic manipulation of the amyloid precursor protein and amyloid Î²-peptides. Expert Opinion on Therapeutic Patents, 1997, 7, 1115-1127.	2.4	10
368	Clinicalâ€“anatomical correlation in a selective phonemic speech production impairment. Journal of the Neurological Sciences, 2004, 219, 23-29.	0.3	10
369	Knightâ€™s move thinking? Mild cognitive impairment in a chess player. Neurocase, 2005, 11, 26-31.	0.2	10
370	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	0.7	10
371	Quantitative Distribution of Neurohypophysial Hormones in Human Brain and Spinal Cord. Progress in Brain Research, 1983, 60, 123-128.	0.9	9
372	Zoster paresis with Horner?s syndrome. Journal of Neurology, 2003, 250, 1492-1493.	1.8	9
373	Pure Progressive Amnesia and the APPV717G Mutation. Alzheimer Disease and Associated Disorders, 2009, 23, 410-414.	0.6	9
374	Exome sequencing reveals a novel partial deletion in the progranulin gene causing primary progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1411-1412.	0.9	9
375	Modelling the occurrence and pathology of Alzheimer's disease. Neurobiology of Aging, 1989, 10, 429-431.	1.5	8
376	Longitudinal (¹⁸F)AV-1451 PET imaging in a patient with frontotemporal dementia due to a Q351R MAPT mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 106-108.	0.9	8
377	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	1.4	8
378	TETRAHYDROAMINOACRIDINE AND ALZHEIMER'S DISEASE. Lancet, The, 1987, 329, 444-445.	6.3	7

#	Article	IF	Citations
379	The Cystatin-C gene is not linked to early onset familial Alzheimer's disease. Neuroscience Letters, 1993, 154, 81-83.	1.0	7
380	Seeing what Alzheimer sawâ€”with magnetic resonance microscopy. Nature Medicine, 2000, 6, 20-21.	15.2	7
381	Supporting clinical research in the NHS in England: the National Institute for Health Research Dementias and Neurodegenerative Diseases Research Network. Alzheimer's Research and Therapy, 2012, 4, 23.	3.0	7
382	Compulsive versifying after treatment of transient epileptic amnesia. Neurocase, 2015, 21, 548-553.	0.2	7
383	CHCHD10Pro34Ser is not a highly penetrant pathogenic variant for amyotrophic lateral sclerosis and frontotemporal dementia. Brain, 2016, 139, e9-e9.	3.7	7
384	Pick's disease is associated with mutations in the tau gene. Annals of Neurology, 2000, 48, 859-867.	2.8	7
385	Postâ€mortem Neurochemistry of Human Brain. Progress in Brain Research, 1986, 65, 167-175.	0.9	6
386	Relationships between Î²-amyloid (AÎ²) deposits and blood vessels in patients with sporadic and familial Alzheimer's disease. Neuroscience Letters, 1996, 207, 171-174.	1.0	6
387	International Medical Workshop covering progressive supranuclear palsy, multiple system atrophy and cortico basal degeneration. Movement Disorders, 2001, 16, 382-395.	2.2	6
388	Inspired by chance: valuing patientsâ€™ informal contributions to research. BMJ, The, 2020, 371, m4478.	3.0	6
389	Screening for the APP codon mutations in Alzheimer's disease. Neuroscience Letters, 1993, 154, 161-162.	1.0	5
390	Central pontine and extrapontine myelinolysis presenting with parkinsonism in a patient with cystic fibrosis. Movement Disorders, 1999, 14, 523-525.	2.2	5
391	Cognitive Impairment and Dementia. , 0, , 245-288.		5
392	Suspected early dementia. BMJ: British Medical Journal, 2011, 343, d5568-d5568.	2.4	5
393	The palmomental reflex: stop scratching around!. Practical Neurology, 2016, 16, 500-501.	0.5	5
394	Alzheimer's disease: the entity and its cause. Biochemical Society Transactions, 1989, 17, 67-69.	1.6	4
395	Exclusion Mapping in Familial Non-Specific Dementia. Dementia and Geriatric Cognitive Disorders, 1993, 4, 163-166.	0.7	4
396	Medial Medullary Syndrome Associated with Patent Foramen ovale in a Weightlifter. European Neurology, 1996, 36, 391-391.	0.6	4

#	Article	IF	Citations
397	Bilateral thalamic pain secondary to bilateral thalamic infarcts relieved by a further unilateral ischaemic episode. European Journal of Neurology, 1999, 6, 717-719.	1.7	4
398	Early diagnosis of dementia. Journal of Neurology, 1999, 246, 4-5.	1.8	4
399	A novel prion protein variant in a patient with semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 890-892.	0.9	4
400	Aphasic Binary Reversals in Patients With Neurological Disease as a Barrier to Clinical Decision Making. JAMA Neurology, 2019, 76, 234.	4.5	4
401	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	1.6	4
402	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	3.0	4
403	Cholecystokinin Content in the Basal Ganglia in Huntington's Disease. Annals of the New York Academy of Sciences, 1985, 448, 488-494.	1.8	3
404	Molecular genetics of Alzheimer's disease. Biochemical Society Transactions, 1989, 17, 75-76.	1.6	3
405	Alzheimer's disease. Postgraduate Medical Journal, 1992, 68, 528-532.	0.9	3
406	O4-05-08 Effects of A-beta immunotherapy (AN1792) on MRI measures of brain, ventricle and hippocampal volumes in Alzheimer's disease. Neurobiology of Aging, 2004, 25, S84-S85.	1.5	3
407	The undiscovered syndrome: Macdonald Critchleyâ€™s case of semantic dementia. Neurocase, 2015, 21, 408-412.	0.2	3
408	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. Movement Disorders, 2021, 36, 632-641.	2.2	3
409	Stability of Pro-Opiocortin-Related Peptides in Post-Mortem Mouse Brain Tissue. Neuroendocrinology, 1982, 35, 336-341.	1.2	2
410	A 38-year-old man with a 9 month history of neurological and cognitive impairment. Lancet Neurology, The, 2003, 2, 189-194.	4.9	2
411	Observations on the human rejection behaviour syndrome: Denny-Brown revisited. Movement Disorders, 2004, 19, 860-862.	2.2	2
412	Does registration of serial MRI improve diagnosis of dementia?. Neuroradiology, 2010, 52, 987-995.	1.1	2
413	F2-03-04: Genetic risk factors for posterior cortical atrophy. , 2015, 11, P168-P169.		2
414	Teaching Neuro Images : Nonfluent variant primary progressive aphasia. Neurology, 2016, 87, e283.	1.5	2

#	Article	IF	Citations
415	O2-04-05: Accelerated Long-Term Forgetting in Presymptomatic Familial Alzheimerâ€™s Disease. , 2016, 12, P231-P231.		2
416	Association between human herpesvirus infections and dementia or mild cognitive impairment: a systematic review protocol. BMJ Open, 2017, 7, e016522.	0.8	2
417	[P1â€“596]: DEVELOPING STANDARDS FOR RESEARCH REGISTERS: APPLYING LEARNING FROM THE U.K.'s NATIONAL â€˜JOIN DEMENTIA RESEARCHâ€™ SERVICE. Alzheimer's and Dementia, 2017, 13, P524.	0.4	2
418	Comparison of digital platforms for participant recruitment in dementia research: Lessons and future directions from a global collaborative. Alzheimer's and Dementia, 2020, 16, e046401.	0.4	2
419	Reply: Functional cognitive disorder: dementiaâ€™s blind spot. Brain, 2021, 144, e73.	3.7	2
420	The Dementia UK Ecosystem: a call to action. Lancet Neurology, The, 2021, 20, 699-700.	4.9	2
421	The Active Brains Digital Intervention to Reduce Cognitive Decline in Older Adults: Protocol for a Feasibility Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e18929.	0.5	2
422	A national openâ€access research registry to improve recruitment to clinical studies. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12221.	1.8	2
423	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	1.1	2
424	Recent advances in the understanding of dementia. Postgraduate Medical Journal, 1988, 64, 99-106.	0.9	1
425	Familial Alzheimer's disease with an APP717 point mutation and sporadic Alzheimer's disease have the same cytoskeletal pathology. Neurobiology of Aging, 1992, 13, S57.	1.5	1
426	International Efforts to Improve Alzheimer Disease Treatment. Alzheimer Disease and Associated Disorders, 1995, 9, 181.	0.6	1
427	Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria.. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 59, 343-343.	0.9	1
428	The cultural context of visual hallucinations. Postgraduate Medical Journal, 2008, 84, 103-105.	0.9	1
429	The Language of Neurology: Symptoms, Signs and Basic Investigations. , 0, , 75-107.		1
430	How dementia and neurodegenerative disease clinical research networks have enhanced research delivery in England. Clinical Investigation, 2014, 4, 687-691.	0.0	1
431	TD-P-004: Harnessing Consumer Technologies and Clinical Data to Improve Recruitment to Clinical Studies: a Review of the First 12 Months of the Join Dementia Research Service in the United Kingdom. , 2016, 12, P153-P153.		1
432	[P2â€“564]: ENCOURAGING PUBLIC PARTICIPATION IN DEMENTIA RESEARCH: ANALYSIS OF TAKEâ€UP AND COSTS FOLLOWING MAIL OUT TO 10,000 PATIENTS WITHIN GENERAL PRACTICE. Alzheimer's and Dementia, 2017, 13, P861.	0.4	1

#	Article	IF	Citations
433	Dementia recognition, diagnosis, and treatment in the UK, 1997â€“2017: a change-point analysis. Lancet, The, 2019, 394, S70.	6.3	1
434	The cognitive footprint of medication: A review of cognitive assessments in clinical trials. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 874-880.	0.7	1
435	A novel presenilin 1 duplication mutation (Ile168dup) causing Alzheimer's disease associated with myoclonus, seizures and pyramidal features. Neurobiology of Aging, 2021, 103, 137.e1-137.e5.	1.5	1
436	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. , 2011, 7, 263.		1
437	Lessons in familial Alzheimerâ€™s disease. , 2001, , 259-265.		1
438	Correlation of regional cerebral amyloid load in Alzheimer's disease, measured with [11C]-PIB pet using spectral analysis and tissue uptake ratios, with Performance on recognition memory tests. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S591-S591.	2.4	1
439	Neuropsychological disorders, dementia, and behavioural neurology. , 2011, , .		1
440	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	1.5	1
441	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	1.7	1
442	Psychiatric symptoms in patients with focal cortical degeneration. Behavioural Neurology, 1994, 7, 153-8.	1.1	1
443	Solitary intracranial plasmacytoma presenting as lateral rectus palsy: Report of a case and review of neuro-ophthalmic manifestations of plasmacytoma. Neuro-Ophthalmology, 1990, 10, 109-113.	0.4	0
444	MRI Findings in an Individual at Risk for Familial Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1993, 4, 120-120.	0.7	0
445	Degenerative diseases. Current Opinion in Neurology, 1996, 9, 251-253.	1.8	0
446	Workshop 1: Differential Diagnosis. International Psychogeriatrics, 1997, 9, 85-86.	0.6	0
447	Dementia in dementia with Lewy bodies may not be attributable to Alzheimer pathology. Annals of Neurology, 2004, 56, 604-604.	2.8	0
448	Survival in Alzheimer Diseaseâ€”Reply. Archives of Neurology, 2005, 62, 689.	4.9	0
449	Microsatellite D21S210 (GT-12) allele frequencies in sporadic Alzheimer's disease. Acta Neurologica Scandinavica, 2009, 91, 145-148.	1.0	0
450	Open biopsy in patients with acute progressive neurologic decline and absence of mass lesion. Neurology, 2011, 76, 1847-1848.	1.5	0

#	Article	IF	Citations
451	O1â€05â€01: Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: Clinical, neuroanatomical and neuropathological features. Alzheimer's and Dementia, 2012, 8, P92.	0.4	0
452	IC-O1-02: Are early atrophy patterns in autosomal dominant familial Alzheimer's disease gene-dependent?. , 2013, 9, P3-P4.		0
453	Neurology in motion. Clinical Medicine, 2013, 13, 443.	0.8	0
454	LONGITUDINAL RESEARCH INTO ALZHEIMER'S DISEASE, FRONTOâ€"TEMPORAL DEMENTIA AND OTHER DEMENTIAS. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.187-e2.	0.9	0
455	COMPULSIVE VERSIFYING IN TRANSIENT EPILEPTIC AMNESIA. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.193-e4.	0.9	0
456	IC-P-175: LONGITUDINAL VOLUMETRIC AND DIFFUSION TENSOR IMAGING IN FAMILIAL ALZHEIMER'S DISEASE. , 2014, 10, P97-P98.		0
457	F1-03-01: DIAN OVERVIEW AND COHORT CHARACTERISTICS. , 2014, 10, P126-P127.		0
458	O1-07-02: LONGITUDINAL VOLUMETRIC AND DIFFUSION TENSOR IMAGING IN FAMILIAL ALZHEIMER'S DISEASE. , 2014, 10, P141-P142.		0
459	IC-P-106: LONGITUDINAL RATES OF ATROPHY IN FAMILIAL ALZHEIMER'S DISEASE. , 2014, 10, P59-P60.		0
460	IC-P-054: Grey matter differences in genetic frontotemporal dementia: Results from the genfi study. , 2015, 11, P42-P42.		0
461	IC-P-117: A cortical signature of familial Alzheimer's disease: Cross-sectional and longitudinal study of presymptomatic changes. , 2015, 11, P80-P81.		0
462	P1-191: Using florbetapir F18 PET to validate CSF cut-points and increase diagnostic certainty in atypical dementias. , 2015, 11, P421-P422.		0
463	P1-211: Genetic influences on amyloid angiopathy and white matter pathology in familial Alzheimer's disease: A comparison of app and PSEN1 mutations. , 2015, 11, P431-P431.		0
464	P2-120: Dementia and music: fMRI signatures of molecular nexopathies. , 2015, 11, P528-P528.		0
465	O3-14-01: Dissecting IWG-2 typical and atypical Alzheimer's disease: Insights from cerebrospinal fluid analysis. , 2015, 11, P254-P254.		0
466	IC-P-049: Detailed structural analysis of the hypothalamus in behavioral variant frontotemporal dementia. , 2015, 11, P39-P40.		0
467	O2-01-06: Measurement of cortical mean diffusivity detects early microstructural breakdown of the cerebral cortex in presymptomatic familial Alzheimer's disease. , 2015, 11, P174-P174.		0
468	O2-10-04: Detailed structural analysis of the hypothalamus in behavioral variant frontotemporal dementia. , 2015, 11, P198-P199.		0

#	Article	IF	Citations
469	IC-P-050: Volumetry of the cerebellum and its subregions in genetic frontotemporal dementia. , 2015, 11, P40-P40.		0
470	IC-P-118: Measurement of cortical mean diffusivity detects early microstructural breakdown of the cerebral cortex in presymptomatic familial Alzheimer's disease. , 2015, 11, P81-P81.		0
471	P2-127: Volumetry of the cerebellum and its subregions in genetic frontotemporal dementia. , 2015, 11, P532-P532.		0
472	O2-01-01: Grey matter differences in genetic frontotemporal dementia: Results from the genfi study. , 2015, 11, P171-P171.		0
473	O2-01-05: A cortical signature of familial Alzheimer's disease: Cross-sectional and longitudinal study of presymptomatic changes. , 2015, 11, P173-P174.		0
474	FTS3-01-04: Setting the Agenda: Prevention Studies for Vascular Contributions to Dementia. , 2016, 12, P277-P277.		0
475	P1â€025: Cerebral Perfusion as an Imaging Biomarker of Presymptomatic Genetic Frontotemporal Dementia: Preliminary Results from the Genetic Frontotemporal Dementia Initiative (GENFI). Alzheimer's and Dementia, 2016, 12, P409.	0.4	0
476	ICâ€Pâ€142: A Longitudinal Morphometric Study of Familial Alzheimerâ€™s Disease: Results from Dian. Alzheimer's and Dementia, 2016, 12, P105.	0.4	0
477	O1â€07â€01: A Longitudinal Morphometric Study of Familial Alzheimerâ€™s Disease: Results From DIAN. Alzheimer's and Dementia, 2016, 12, P187.	0.4	0
478	F5â€02â€02: Longitudinal Atrophy in Autosomal Dominant Ad and Sporadic Ad: Lessons from Dian. Alzheimer's and Dementia, 2016, 12, P368.	0.4	0
479	F5â€02â€03: BDNF VAL66MET Moderates Cognitive Impairment, Neuronal Dysfunction and TAU in Preclinical Autosomal Dominant Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P369.	0.4	0
480	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network. , 2016, 12, P378-P379.		0
481	Better together for better dementia research and care. Lancet Psychiatry,the, 2016, 3, 503-504.	3.7	0
482	FTS2-01-05: From the who Research Priorities and Research Portfolio Analysis to the Identification of Research Gaps to Reduce the Global Burden of Dementia. , 2016, 12, P220-P220.		0
483	[P2â€“441]: PATHOLOGICAL CORRELATES OF WHITE MATTER HYPERINTENSITIES ON CADAVERIC MRI IN PROGRANULINâ€ASSOCIATED FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P805.	0.4	0
484	[P2â€“477]: DONEPEZIL MODULATES PERCEPTUAL LEARNING IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P823.	0.4	0
485	[P3â€“208]: EFFECT OF DONEPEZIL ON TRANSCRANIAL MAGNETIC STIMULATION PARAMETERS IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1015.	0.4	0
486	[P3â€“558]: DEMENTIAS PORTFOLIO DEVELOPMENT ACTIVITIES: UNITING AND SUPPORTING THE RESEARCH COMMUNITY TO INCREASE RESEARCH INCOME. Alzheimer's and Dementia, 2017, 13, P1192.	0.4	0

#	Article	IF	Citations
487	[ICâ€Pâ€150]: CHARACTERISING PRESYMPTOMATIC ATROPHY PATTERNS THROUGH MULTIVARIATE MACHINE LEARNING. Alzheimer's and Dementia, 2017, 13, P113.	0.4	0
488	[P1â€“335]: THEMES AND VARIATIONS IN PPA: A CLINICAL AND NEUROBIOLOGICAL ANALYSIS OF THE UCL COHORT. Alzheimer's and Dementia, 2017, 13, P384.	0.4	0
489	[O1â€“02â€“02]: CHARACTERISING PRESYMPTOMATIC ATROPHY PATTERNS THROUGH MULTIVARIATE MACHINE LEARNING. Alzheimer's and Dementia, 2017, 13, P185.	0.4	0
490	[F4â€“01â€“04]: NEUROIMAGING AND HETEROGENEITY IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1211.	0.4	0
491	[O4â€“02â€“04]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER's DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY. Alzheimer's and Dementia, 2017, 13, P1230.	0.4	0
492	[P4â€“570]: A DOUBLEâ€BLIND PLACEBOâ€CONTROLLED CROSSâ€OVER CLINICAL TRIAL OF DONEPEZIL IN POSTERIOR CORTICAL ATROPHY DUE TO UNDERLYING ALZHEIMER's DISEASE: DONIPAD STUDY. Alzheimer's and Dementia, 2017, 13, P1571.	0.4	0
493	P2â€438: ROBUST IDENTIFICATION OF BRAIN STRUCTURES MOST DISCRIMINATIVE IN DETECTING EARLY CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P882.	0.4	0
494	O2â€04â€04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P623.	0.4	0
495	ICâ€Pâ€048: SAMPLE SIZE ESTIMATES FOR SECONDARY PREVENTION STUDIES USING REGIONAL ATROPHY RATES. Alzheimer's and Dementia, 2018, 14, P47.	0.4	0
496	ICâ€Pâ€165: ROBUST IDENTIFICATION OF BRAIN STRUCTURES MOST DISCRIMINATIVE IN DETECTING EARLY CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P138.	0.4	0
497	P1â€410: SAMPLE SIZE ESTIMATES FOR SECONDARY PREVENTION STUDIES USING REGIONAL ATROPHY RATES. Alzheimer's and Dementia, 2018, 14, P461.	0.4	0
498	P4â€130: IMPLEMENTING POLICY AND SYSTEM CHANGE TO MAKE OFFERING CLINICAL RESEARCH A STANDARD PART OF DEMENTIA CARE PATHWAYS IN THE UNITED KINGDOM. Alzheimer's and Dementia, 2018, 14, P1488.	0.4	0
499	P3â€261: SERUM NEUROFILAMENT LIGHT CONCENTRATION AND PROGRESSION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1174.	0.4	0
500	Foundation and Making of the National Hospital. , 0, , 6-50.		0
501	Queen Square, the Salmon Pink and Other Hospital Buildings. , 0, , 51-97.		0
502	Queen Square and Neurology 1860â€“1902. , 0, , 98-129.		0
503	National Hospital Quadrumvirate. , 0, , 130-168.		0
504	Roller-coaster Ride and the National Hospital Rubs Along 1902â€“1945. , 0, , 169-215.		0

#	Article	IF	Citations
505	Five Dominant Physicians. , 0, , 216-255.		0
506	The NHS Arrives and the Hospital Celebrates its Centenary 1946â€“1962. , 0, , 256-286.		0
507	Beyond the Walls: British Neurology Outside Queen Square. , 0, , 287-307.		0
508	Neurosurgery and War Neurology at Queen Square. , 0, , 308-339.		0
509	Other Clinical Specialties at Queen Square. , 0, , 340-380.		0
510	The Investigatory Specialties at Queen Square. , 0, , 381-417.		0
511	The Medical School and the Institute of Neurology. , 0, , 418-438.		0
512	The Rise of Academic Neurology at Queen Square 1962â€“1997. , 0, , 439-476.		0
513	Never, Never, Ever â€“ Change and Integration 1962â€“1997. , 0, , 477-521.		0
514	One hundred years of shared interest. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 225-226.	0.9	0
515	Plasma phosphoâ€tau in familial Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042921.	0.4	0
516	A crossâ€sectional study of memory and executive functions in patients with sporadic inclusion body myositis. Muscle and Nerve, 2021, 65, 105.	1.0	0
517	Psychologically determined disorders. , 2011, , .		0
518	IN 2014 CAN WE PREVENT DEMENTIA?. Transactions of the Medical Society of London, 2013, 130, 59-63.	0.2	0